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Abstract: Siponimod (BAF312) is a synthetic molecule belonging to the sphingosine-1-phosphate 
(S1P) modulator family, which has putative neuroprotective properties and well-characterized 
immunomodulating effects mediated by sequestration of B and T cells in secondary lymphoid 
organs. Compared to fingolimod (ie, precursor of the S1P modulators commercially available for 
the treatment of relapsing–remitting [RR] multiple sclerosis [MS]), siponimod exhibits selective 
affinity for types 1 and 5 S1P receptor, leading to a lower risk of adverse events that are mainly 
induced by S1P3 receptor activation, such as bradycardia and vasoconstriction. In addition, 
S1P1 and S1P5 receptors are expressed by neurons and glia and could mediate a possible 
neuroprotective effect of the drug. A Phase II clinical trial of siponimod for RR MS showed a 
significant effect of the active drug compared to placebo on reducing gadolinium-enhancing 
lesions on brain magnetic resonance imaging (MRI) after 3 months of treatment. In a recently 
completed Phase III trial, treatment with siponimod was associated with a significant reduction 
in disability progression in secondary progressive (SP) MS patients compared to placebo. In this 
article, current evidence supporting siponimod efficacy for SP MS is reviewed.
Keywords: multiple sclerosis, siponimod, progression, disability, treatment
Background
Secondary progressive (SP) multiple sclerosis (MS) is a clinical subtype of the 
disease characterized by continuous worsening of neurological disability that begins 
insidiously in patients with a preceding relapsing–remitting (RR) course, which is the 
mode of onset of ~90% of cases. The risk and timing of transition from RR MS to SP 
MS are highly unpredictable in the individual MS patient; however, it is estimated 
that up to 90% of RR MS cases may evolve to SP MS over a 25-year time interval.1 
While patients with RR MS tend to recover fully or partially after relapses and may 
experience mild neurological symptoms, SP MS cases usually have gradual – although 
not necessarily steady – accumulation of neurological disability, typically affecting 
walking, sphincter control, hand function, speech, swallowing, and cognition. In addi-
tion, several disease-modifying therapies (DMTs) have shown efficacy in reducing 
relapses and overall disease activity in RR MS, while the majority of these and other 
investigational treatments have failed to prevent disease worsening in progressive 
MS.2 This may be explained by the predominance of acute inflammation, which is 
the main biological target of available MS DMTs, in the pathophysiology of RR MS 
clinical manifestations, ie, relapses that are known to decrease in frequency or even 
cease after the transition to an SP course. However, in the pathological continuum 
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between RR MS and SP MS, other factors may play a role, 
such as the effect of longstanding inflammation; exhaustion 
of compensatory and reparative mechanisms; and genetic, 
age-dependent, and exogenous factors.3 Approved DMTs 
for MS have little or no effect on the regulation of these 
biological processes as demonstrated by the modest or absent 
benefit of most treatments on disability progression that is 
independent of relapses.
Recently, a large Phase III placebo-controlled trial 
of the investigational agent siponimod for SP MS met 
its primary efficacy end point, showing a statistically 
significant reduction in confirmed disability progression 
in patients receiving the experimental intervention.4 The 
present article reviews the characteristics and development 
of siponimod and discusses its potential for future clinical 
use in MS.
“Discovery” of BAF312 (siponimod)
Siponimod (BAF312) is a structural analog of sphingosine, 
which is an endogenous sphingolipid involved in the regula-
tion of a variety of biological functions, including lymphocyte 
trafficking, cardiomyocyte function, vascular development, 
and cell survival.5 Sphingosine-1-phosphate (S1P) is the 
bioactive metabolite of sphingosine in vivo, which binds to 
a family of G-protein-coupled receptors consisting of five 
distinct subtypes (S1PR1–S1PR5) expressed differentially 
on the surface of several cell types, eg, myocytes (S1PR1 and 
S1PR3), lymphocytes (S1PR1), astrocytes, oligodendrocytes, 
and neurons (S1PR1 and S1PR5). Of importance for immune 
system regulation, interaction of S1P with S1PR1 is essential 
for the egression of a subset of lymphocytes from secondary 
lymphoid organs and their redistribution to other tissues. The 
discovery that a chemically modified natural sphingolipid (ie, 
fingolimod) exhibits immunosuppressive effects after in vivo 
phosphorylation, by functionally antagonizing S1PR1 and 
thus sequestrating B and T cells in lymphoid tissues, led to 
the clinical development and approval of this molecule for the 
treatment of RR MS.6 However, fingolimod also has affinity 
for other S1PR subtypes, including S1PR3 that is internalized 
by cardiac myocytes after interaction with the phosphorylated 
form of the drug, leading to heart rate reduction, and rarely 
to atrioventricular block and cardiac arrest, particularly in 
the first 24 hours after treatment start. It is therefore recom-
mended to perform 6-hour cardiac monitoring in all patients 
initiating fingolimod. In addition, fingolimod has a prolonged 
half-life in human beings requiring ~2 months for elimination 
after treatment interruption. These limitations prompted the 
pharmaceutical industry to develop S1PR modulators with 
shorter half-life and lacking affinity for S1PR3 with the 
objective of combining fingolimod efficacy for MS with a 
better pharmacokinetic and safety profile.
Siponimod is a synthetic derivative of fingolimod 
obtained with modifications providing increased rigidity 
in the lipophilic alkyl chain, which confers selectivity for 
S1PR1 and SIPR5 as shown in vitro.7 In vivo preclinical 
studies showed that siponimod was safe and significantly 
ameliorated symptoms of the murine animal model of MS 
(ie, experimental autoimmune encephalitis [EAE]),8 opening 
the way to the development of clinical trials of BAF312 for 
patients with MS.
Siponimod clinical development 
for MS
An exploratory Phase I trial of siponimod showed that 
drug administration was overall safe at multiple doses in a 
group of 48 healthy volunteers, although it induced transient 
(day 1 only) bradycardia despite sparing of S1PR3. In fact, 
BAF312 activates GIRK channels in human atrial myocytes 
likely through interaction with S1PR1, causing bradycardia.8 
Pharmacokinetic analysis revealed that siponimod half-life 
is 30 hours with complete drug elimination in ~7 days. Fol-
lowing these findings, a dose-ranging randomized Phase II 
trial assessed the safety and efficacy of BAF312 vs placebo 
(BOLD study) in two independent cohorts of patients with 
RR MS enrolled in 72 centers.9 Subjects in cohort 1 (N=188) 
received once daily siponimod 10 mg, 2 mg, 0.5 mg, or 
placebo (1:1:1:1) for 6 months. After a 3-month interim 
analysis, 109 additional patients were allocated to once daily 
siponimod 1.25 mg, 0.25 mg, or placebo (4:4:1) for 3 months 
(cohort 2). Patients in cohort 1 immediately received the 
full siponimod dose, while in cohort 2, a masked titration 
scheme was implemented for treatment initiation. The pri-
mary outcome was the dose–response relationship of the five 
doses of siponimod compared with placebo during 3 months 
of treatment, based on the number of new gadolinium-
enhancing lesions on T1-weighted images and new or newly 
enlarged non-enhancing lesions on T2-weighted monthly 
brain magnetic resonance imaging (MRI) scans. Secondary 
end points included also clinical efficacy measures, such 
as annualized relapse rate and proportion of relapse-free 
patients, and safety/tolerability data. Siponimod doses of 
10, 2, 1.25, and 0.5 mg significantly reduced the number of 
new brain lesions (as defined in the primary end point) at 
3 months compared to placebo with a dose-dependent rela-
tion. In addition, siponimod 2 mg significantly reduced the 
annualized relapse rate at 6 months compared to placebo. 
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A dose-dependent decrease in heart rate was observed dur-
ing treatment initiation on day 1, reaching nadir at ~3 hours 
after dosing and returning to levels similar to placebo in the 
following 24 hours in all treatment groups. Dose titration 
(siponimod 1.25 mg group) mitigated heart rate reduction 
compared to full-dose administration on day 1. First- and 
second-degree atrioventricular blocks were reported in nine 
patients receiving siponimod 10, 2, or 0.5 mg. As expected, 
there was a dose-dependent total lymphocyte count decrease 
by 20%–74% at day 7 of siponimod treatment compared 
to baseline, which remained stable up to 3 and 6 months. 
Increased alanine aminotransferase concentrations were 
reported more frequently in the siponimod groups compared 
to placebo. In the 24-month extension of the trial, patients 
receiving siponimod continued with the originally allocated 
dose, while patients on placebo were randomized at base-
line to one of the five siponimod doses.10 The incidence of 
adverse events was similar across treatment groups. Nine out 
of 252 enrolled patients had serious adverse events, but no 
new or unexpected safety concerns emerged compared to the 
core BOLD study. The number of gadolinium-enhancing T1 
lesions and new T2 lesions on brain MRI and the annualized 
relapse rates remained low over 24 months, particularly with 
the three or four highest siponimod doses.
In 2012, a large randomized, placebo-controlled, double-
blind Phase III trial of siponimod for SP MS (EXPAND 
study) was started in 31 countries.4 Eligible patients were 
aged 18–60 years, had progressive increase in disability for 
at least 6 months in the absence or independent of relapses, 
and a baseline Expanded Disability Status Scale (EDSS) 
score from 3.0 to 6.5. The primary efficacy outcome was 
time to 3-month confirmed disability progression mea-
sured by EDSS. The key secondary outcomes were time to 
confirmed worsening of $20% from baseline in the timed 
25-foot walk test and brain T2 lesion volume change from 
baseline. The study enrolled 1,651 patients (60% women) 
who were randomized 2:1 to receive either siponimod 2 mg 
daily (with initial 6-day dose titration starting at 0.25 mg) 
or placebo for a variable duration determined by the time 
at which a prespecified number of patients reached the pri-
mary outcome in the overall study population. At baseline, 
mean age was 48 years, median EDSS score was 6.0, and 
75% of patients had no gadolinium-enhancing T1 lesions. 
In addition, relapses in the 2 years prior to study start were 
documented in 35% of patients.11 Of the 1,651 included 
patients, 1,363 (83%) completed the study. Median time 
on study was 21 months, with the majority of patients 
(87%) participating for at least 1 year. Overall, there were 
449 confirmed disability progression events. Treatment 
with siponimod was associated with 21% reduction in the 
risk of disability progression confirmed at 3 months (26% 
at 6 months) compared to placebo (hazard ratio =0.79, 
p=0.013 and hazard ratio =0.74, p=0.006, respectively). 
Accordingly, siponimod treatment showed a beneficial 
effect on other secondary efficacy outcomes, including the 
annualized relapse rate, T2 lesion volume, new T2 lesions, 
and number of gadolinium-enhancing lesions (p,0.0001 for 
all comparisons vs placebo). In addition, a benefit on percent 
brain volume change was also reported in patients receiving 
siponimod (p=0.0002 vs placebo). Siponimod did not show 
a significant benefit on ambulation impairment as measured 
by timed 25-foot walk. Adverse events in the siponimod 
group occurred at a similar rate (88.7%), to that observed 
in the previous BOLD RR MS trial, leading to treatment 
discontinuation in 7.6% of patients. Most common adverse 
events (.10%) were headache, nasopharyngitis, urinary 
tract infection, falls, and hypertension. Serious adverse 
events occurred in 17.9% of patients on siponimod and 
15.2% of patients receiving placebo. Incidence of deaths 
(0.4% vs 0.7%), malignancies (1.9% vs 2.6%), and infections 
(49.0% vs 49.1%) was similar between treatment groups. 
Adverse events of interest included bradyarrhythmias (3.5% 
vs 2.4%), hypertension (12.6% vs 9.3%), and macular edema 
(1.8% vs 0.2%). Lymphopenia ,0.2×109/μL was observed 
in 2.7% vs 0.2% of patients, and liver function test elevation 
was three or more times greater than upper normal limit in 
5.6% vs 1.5% of patients.12
Discussion – insights into potential 
siponimod efficacy for SP MS
SP MS is characterized by irreversible accrual of disability 
over time as a consequence of insidious worsening of neu-
rological symptoms rather than failure of relapse recovery. 
This type of MS course is lacking a substantially effective 
treatment to reduce disability progression independent of 
relapses. The results reported for the siponimod Phase III SP 
MS study (ie, the largest clinical trial for SP MS ever) are 
encouraging, although the final data have still to be published 
in a full peer-reviewed paper. Based on available information, 
siponimod showed a statistically significant effect on reduc-
ing confirmed EDSS progression over ~2 years of treatment 
on average compared to placebo. This finding was consistent 
with the reduction in the relapse rate during the trial and the 
effect favoring siponimod on several MRI measures, includ-
ing brain atrophy, new/enlarging T2 lesions, and gadolinium-
enhancing lesions. However, there was a discrepancy with the 
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data observed for a key secondary clinical end point, ie, gait 
speed measured by timed 25-foot walk, on which treatment 
with siponimod did not show a significant benefit. Although 
the full data analysis is not published yet, the magnitude of 
siponimod effect on the primary end point of the EXPAND 
trial (ie, 21% reduction of 3-month confirmed EDSS score 
progression compared to placebo) appears robust and sug-
gests a possible clinically meaningful benefit of the drug, 
particularly because of the scarcity of effective therapies 
for SP MS patients.
Currently approved DMTs for SP MS include interferon 
beta-1b and mitoxantrone, based on the results of two clinical 
trials that showed some benefits of these drugs on disability 
progression compared to placebo. In the trial conducted by 
the European Study Group on interferon beta-1b in SP MS, 
patients treated with interferon showed significantly less 
EDSS progression that was confirmed at 3 months compared 
to patients receiving placebo over 3 years (39% vs 50%).13 
In the trial of mitoxantrone for rapidly progressive MS, 
patients on active drug had a stable or improved EDSS score 
at 2 years in a significantly higher proportion than patients 
treated with placebo (mean EDSS change -0.13 vs +0.23).14 
Both studies recruited an “active” SP MS population, char-
acterized by a high pretrial relapse rate and/or presence 
of gadolinium-enhancing lesions on baseline brain MRI. 
Post hoc analyses demonstrated that most of the effects on 
disability progression observed with interferon beta and 
mitoxantrone were actually driven by the significant relapse 
rate reduction determined by the active drugs rather than by 
halting disability progression per se. In fact, other trials of 
interferon beta-1a and -1b enrolling SP MS patients with 
lower prestudy relapse rate failed to show a significant benefit 
on EDSS progression.15 Similarly, several additional clinical 
trials were not able to consistently show a significant benefit 
of immunomodulatory and immunosuppressive drugs on dis-
ability progression in SP MS patients, with few exceptions.16 
Among therapies not directly targeting the immune system, 
high-dose biotin (MD1003) has been recently investigated 
in a Phase III trial that enrolled 154 patients with SP or 
primary progressive (PP) MS and met its innovative primary 
end point, ie, the proportion of patients with disability 
reversal at month 9, confirmed at month 12, defined as an 
EDSS decrease of $1 point ($0.5 for baseline EDSS 6–7) 
or a $20% decrease in timed 25-foot walk.17 In this study, 
13% of patients (mostly SP MS cases) treated with MD1003 
reached the primary efficacy outcome compared to none 
of the patients receiving placebo. Interestingly, .40% of 
subjects in the MD1003 group were on a concomitant DMT, 
suggesting that high-dose biotin may be safely administered 
in progressive MS patients as add-on treatment to immuno-
modulatory or immunosuppressive drugs.
Different from most previous positive SP MS studies, 
the EXPAND siponimod trial design and inclusion criteria 
allowed the enrollment of a widely representative SP MS 
population, characterized by evidence of disease progression 
with low relapse rate prior to study initiation and low propor-
tion of gadolinium-enhancing lesions on baseline brain MRI. 
In this view, it seems unlikely that the effect observed on 
disability progression could be explained purely by relapse 
rate reduction and/or amelioration of disease processes 
reflected by MRI activity. In vitro and animal model studies 
have shown that, beside the immunomodulatory effects 
driven by lymphocyte trafficking regulation, siponimod 
may have protective properties against demyelination and 
neurodegeneration. O’Sullivan et al18 demonstrated that 
BAF312 activates pERK, pAKT, and calcium signaling 
(ie, molecular pathways involved in the regulation of cell 
survival and proliferation) in cultured mouse and human 
astrocytes, mainly through interaction with S1PR1. In the 
same study, treatment with siponimod attenuated demyeli-
nation induced in organotypic slice cultures prepared from 
mouse cerebellum. Recently, Gentile et al19 showed that intra-
cerebroventricular infusion of siponimod in mice with EAE 
rescued defective GABAergic transmission and prevented 
GABAergic interneuron loss, which are at the basis of an 
inflammation-dependent synaptopathy possibly contributing 
to neurodegeneration and irreversible disability accumulation 
in demyelinating disease models. Furthermore, the investi-
gators reported reduced release of IL-6 and RANTES from 
activated microglial cells in vitro after BAF312 treatment, in 
addition to astrogliosis and microgliosis reduction together 
with lymphocyte infiltration attenuation in the striatum of 
EAE mice treated with siponimod.
The potential neuroprotective effect of siponimod sug-
gested by these studies could explain the benefit observed 
on disability progression in patients with SP MS treated 
with this drug.
In contrast with these findings, the INFORMS trial 
failed to show a significant effect of fingolimod vs placebo 
on 3-month confirmed disease progression (measured on a 
composite end point including EDSS score, 9-hole peg test, 
and timed 25-foot walk test) in a large population (n=970) 
of PP MS patients followed for at least 3 years.20 Besides the 
different primary end points of the EXPAND and INFORMS 
trials, other factors may explain the divergent findings of the 
two studies.21 The EXPAND trial had an adaptive design in 
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terms of duration, since the trial was stopped when a predeter-
mined number of events were reached. This methodological 
strategy might have enhanced the likelihood of detecting 
an effect of treatment compared to the PP MS fingolimod 
trial. Other possible explanations of the success of the 
siponimod trial as opposed to the failure of the fingolimod 
one in progressive MS are the intrinsic pathogenetic differ-
ences between SP and PP MS and the selective interaction 
of siponimod with types 1 and 5 S1PR, which are known to 
mediate protective effects on oligodendrocytes, microglia, 
astrocytes, and neurons.22 Overall, S1PR modulators family 
seems to represent a promising treatment strategy for MS as 
indicated by the recent findings of ponesimod, ozanimod, and 
amiselimod Phase II trials in relapsing MS.23–25
Publication of final data of the EXPAND trial and further 
research to confirm the promising results of siponimod and 
other S1PR modulators studies in MS are warranted.
Disclosure
The author reports no conflicts of interest in this work.
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